Zeneca Acquires US Rights to Kadian, an Oral Morphine Product

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WILMINGTON, Del--Zeneca Inc. has reached an agreement with Faulding Services Inc. (Adelaide, South Australia) for exclusive US rights to purchase, distribute, and promote Faulding's sustained-release morphine sulfate product Kadian, an oral medication taken once or twice daily.

WILMINGTON, Del--Zeneca Inc. has reached an agreement with FauldingServices Inc. (Adelaide, South Australia) for exclusive US rightsto purchase, distribute, and promote Faulding's sustained-releasemorphine sulfate product Kadian, an oral medication taken onceor twice daily.

A new drug application (NDA) for use of Kadian in the treatmentof moderate to severe chronic pain is currently under FDA review.The product is approved and available in Australia and severalEuropean countries.

Articles in this issue
No Need to Delay Mammography After FNA, Study Shows
Pediatric Cancer Guidelines Are a National Effort
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutants
ATL's HDI Digital Ultrasound Is Approved for Breast Indication
Cell-Adhesion Molecules May Be Key to Controlling Metastases in Breast Cancer
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C
Natural History of HIV Supports the Use Of Early Interventions
Aids Vaccine Trial Fails to Show Clinical Benefit
Rep. Porter Honored For Work on Budget
Forum Airs Issue of Who Should Pay for Patient Care in Cancer Clinical Trials
Blenoxane Cleared for New Use In Malignant Pleural Effusion
Implementation of Critical Path Reduces Prostatectomy Costs
Berlex Foundation Seeks Workshop Applicants
Networking Venture Benefits Both
Health of Biotech Industry a Concern to Oncologists

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content
Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission

Russ Conroy
August 5th 2025
Article

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 5th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 5th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 5th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

INKmune Exhibits Favorable Safety in Metastatic CRPC

Roman Fabbricatore
August 5th 2025
Article

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.

Aumolertinib Has Long-Term Survival Benefit in NSCLC With Brain Metastases

Russ Conroy
August 5th 2025
Article

Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.